---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-22-001913"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2022-09-02T23:59:59+00:00"
generated_at: "2026-06-23T16:20:15.717016+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Lexaria Bioscience appoints Catherine Turkel to board; grants stock options, receives Mexican patent

## Summary
- Appointed Catherine Turkel, PharmD, PhD as independent director; board expanded to six members effective Sept 2, 2022.
- Dr. Turkel brings 20+ years pharma exec experience; led Allergan's BOTOX Chronic Migraine registration program.
- Compensation set parallel to other independent directors; contributes to drug development and Nasdaq diversity goals.
- Granted 103,500 options at $2.91 expiring Aug 2027 to employees/directors/officers; 3,400 options at $3.04 expiring Sep 2027 to a director.
- Awarded Mexican patent #390001 for stable ready-to-drink lipophilic active agent beverage compositions (grant date Feb 10, 2022).

## SEC filing metadata
- accession: 0001640334-22-001913
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2022-09-02T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033422001913/0001640334-22-001913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033422001913/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-22-001913
- JSON: https://secwatch.observer/filing/0001640334-22-001913.json
- Plain text: https://secwatch.observer/filing/0001640334-22-001913.txt

## Key facts
- Executive change
  Catherine C. Turkel was appointed as Independent Director at Lexaria Bioscience Corp..
  - Action: appointed
  - Role: Independent Director
  source text: On September 2, 2022 (the “Effective Date”) the board of directors of Lexaria Bioscience Corp., in accordance with Nevada corporate laws, increased the size of the board to six members and appointed Catherine C. Turkel, PharmD, PhD as an additional independent director to hold such position until the next shareholder’s meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033422001913/0001640334-22-001913-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.